Gastro-Resistant Posaconazole Formulation for High Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing high-strength posaconazole formulations are too large for easy swallowing and result in premature drug precipitation, leading to decreased bioavailability when administered orally.
Innovation Solution
A gastro-resistant pharmaceutical composition comprising 300 mg posaconazole molecularly dispersed in a mixture of enteric and non-enteric polymers, prepared by hot-melt extrusion, with a weight ratio of enteric polymer to posaconazole ranging from 3.3:1 to 1.5:1, ensuring bioavailability and patient comfort.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the drug concentration is increased to provide high-strength formulation, then the dosage strength is improved, but the tablet size becomes too large for comfortable swallowing
Solution Approach 1:
The formulation segments the drug at molecular level by dispersing posaconazole molecules individually within the polymer matrix, preventing aggregation and enabling high drug concentration in compact form. This molecular dispersion allows 300 mg of posaconazole to be contained in a swallowable tablet size by eliminating intermolecular spaces that would otherwise increase tablet volume.
Solution Approach 2:
The patent changes the physical state parameter of the drug from crystalline to molecularly dispersed state within the polymer matrix. This parameter change enables higher drug loading density while maintaining small tablet size, as the molecular dispersion eliminates the need for crystalline lattice structures that occupy more space.
2Quantity of substance
If the drug concentration is increased to provide high-strength formulation, then the dosage strength is improved, but the drug precipitates prematurely in gastric fluid
Solution Approach 1:
The polymer matrix acts as an intermediary between the drug and gastric fluid. It molecularly disperses posaconazole and maintains this dispersion state during gastric transit, preventing premature precipitation. The polymer barrier ensures the drug remains solubilized until intestinal release, where pH conditions favor drug stability.
Solution Approach 2:
The formulation creates a composite material system where posaconazole is molecularly dispersed within a polymer matrix. This composite structure provides both high drug concentration capability and enhanced stability, as the polymer environment prevents drug-drug interactions that would lead to precipitation while maintaining swallowable tablet size.
3Ease of manufacture
If conventional formulation methods are used, then the manufacturing process is simple, but the bioavailability is insufficient
Solution Approach 1:
The patent applies parameter changes by controlling the molecular dispersion state of the drug within the polymer matrix during manufacturing. This parameter control (maintaining molecular dispersion rather than allowing crystallization) significantly enhances bioavailability while the formulation can still be manufactured using conventional hot-melt extrusion and compression techniques, balancing manufacturing simplicity with improved performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains high bioavailability by resisting gastric fluids and releasing the drug in the intestines, while being compact enough for easy swallowing, thus improving patient compliance.
Implementation Method 1
gastro-resistant tablet has an improved bioavailability and can be administered without regard to food
Implementation Method 2
300 mg posaconazole molecularly dispersed in a mixture comprising an enteric polymer and a non-enteric polymer, wherein the mixture is prepared by hot-melt extrusion
Implementation Method 3
Different crystalline forms of a drug usually exhibit different dissolution profiles, whereby amorphous forms are generally much more soluble than their crystalline counterparts
Data Source
AI summary
A gastro-resistant high-strength unit dosage form includes a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or an optionally film-coated tablet.